MYOV Myovant Sciences Ltd.

11.17
-0.2  -2%
Previous Close 11.37
Open 10.98
Price To Book -20.68
Market Cap 1,002,932,563
Shares 89,788,054
Volume 1,285,037
Short Ratio 4.56
Av. Daily Volume 883,203
Stock charts supplied by TradingView

NewsSee all news

  1. Hercules Capital Reports Fourth Quarter and Record Full-Year 2019 Financial Results

    Company Achieves Multiple Records for FY 2019: Total New Debt and Equity Commitments, Total Gross Fundings, Total Investment Income, Net Investment Income, Total Investment Assets and Total Debt Investments among

  2. Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2019

    - 96.7% response rate in Phase 3 HERO study support submission of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer in the second quarter of calendar year 2020 - 87.7% one-year

  3. Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

    Primary efficacy endpoint met with 87.7% response rate at one year; women experienced, on average, an 89.9% reduction in menstrual blood loss  Bone mineral density maintained through one year, with no new safety signals

  4. Myovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

    BASEL, Switzerland, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn

  5. Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions

    Low-interest (3-month LIBOR plus 3%) loan facility from Sumitomo Dainippon Pharma increased to allow repayment of pre-existing debtHiroshi Nomura, President, CEO, and Representative Director of Sumitomo Dainippon Pharma

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data 2Q 2020.
Relugolix - SPIRIT 1
Endometriosis-associated pain
Phase 3 data due 1Q 2020.
Relugolix - SPIRIT 2
Endometriosis-associated pain
NDA filing due 2Q 2020.
Relugolix - HERO
Advanced prostate cancer
NDA filing due April 2020.
Relugolix - LIBERTY 1 and LIBERTY 2
Menstrual bleeding associated with uterine fibroids

Latest News

  1. Hercules Capital Reports Fourth Quarter and Record Full-Year 2019 Financial Results

    Company Achieves Multiple Records for FY 2019: Total New Debt and Equity Commitments, Total Gross Fundings, Total Investment Income, Net Investment Income, Total Investment Assets and Total Debt Investments among

  2. Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2019

    - 96.7% response rate in Phase 3 HERO study support submission of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer in the second quarter of calendar year 2020 - 87.7% one-year

  3. Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

    Primary efficacy endpoint met with 87.7% response rate at one year; women experienced, on average, an 89.9% reduction in menstrual blood loss  Bone mineral density maintained through one year, with no new safety signals

  4. Myovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

    BASEL, Switzerland, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn

  5. Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions

    Low-interest (3-month LIBOR plus 3%) loan facility from Sumitomo Dainippon Pharma increased to allow repayment of pre-existing debtHiroshi Nomura, President, CEO, and Representative Director of Sumitomo Dainippon Pharma

  6. Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

    BASEL, Switzerland, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn

  7. Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer

    Primary efficacy endpoint met with 96.7% of men achieving sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeksAchieved all six key secondary endpoints, including superiority to

  8. Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, November 19 to Discuss Results from Phase 3 Study Evaluating Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer

    BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced it will

  9. Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2019

    -Landmark Agreement with Sumitomo Dainippon Pharma to provide major financial backing and safeguards for minority shareholders -Myovant to report top-line data from Phase 3 HERO study in advanced prostate cancer by the

  10. Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders

    Sumitomo Dainippon Pharma to provide Myovant Sciences with a $350 million, low-interest, five-year term loan facility, with no repayments due until the end of the termOpportunity to access Sumitomo Dainippon Pharma's

  11. Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis

    Top-line results for SPIRIT 2 and SPIRIT 1 expected in the first and second quarters of 2020, respectivelyStudies support potential regulatory submission for a single tablet, once-daily treatment of moderate-to-severe

  12. Myovant Sciences Announces Late-Breaking Oral Presentation of Phase 3 LIBERTY 1 & 2 Study Results at 2019 American Society for Reproductive Medicine Scientific Congress

    BRISBANE, Calif., and BASEL, Switzerland, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer,

  13. Myovant Sciences' Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance

    Roivant's ownership interest in Myovant Sciences (approximately 46% of shares issued and outstanding) to be fully assumed by a new entity, Sumitomo Dainippon-Roivant Alliance, which will be wholly owned by Sumitomo

  14. Myovant Sciences to Participate in Upcoming September Investor Conferences

    BRISBANE, Calif. and BASEL, Switzerland, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women's